20 years of Alzheimer's clinical trials: a meta-analysis

Samuel Dickson, PhD, Pentara Corporation, Millcreek, UT, outlines an ongoing meta-analysis that looks into all Alzheimer’s disease (AD) clinical trials over past 20 years. Three main outcomes were targeted: Clinical Dementia Rating Sum of Boxes (CDR-SB), Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), and Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL). The study aims to compare treatment effects for early and mild-to-moderate Alzheimer's using these outcomes individually and in combination. Preliminary results show that the recent monoclonal antibodies are performing well, but also highlight previously overlooked treatments like rotigotine which showed effect sizes comparable to established options. This interview took place at the American Academy of Neurology (AAN) Annual Meeting 2024 in Denver, CO.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.